Synlogic Announces Contract with the Air Force Research Lab
December 27, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
December 07, 2023 07:00 ET
|
Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
November 07, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
October 03, 2023 16:15 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
September 29, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
July 11, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
June 28, 2023 07:00 ET
|
Synlogic, Inc.
The World Health Organization has approved “labafenogene marselecobac”Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria communityCAMBRIDGE, Mass., June...
iBio Receives US and European Patents for Protein Expression Technology
February 12, 2015 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 12, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issuance of...
iBio Adds to iBioModulator Portfolio and Product Pipeline
February 04, 2015 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 4, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, today announced the issue of a new...
iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
December 10, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Dec 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and...